Neurohormonal Activation in Heart Failure with Reduced Ejection Fraction

Overview

Journal Nat Rev Cardiol

Specialty Cardiology & Vascular Diseases

Date 2016 Oct 7

PMID 27708278

Citations 239

Authors

Justin Hartupee

Douglas L Mann

Affiliations

Soon will be listed here.

Abstract

Heart failure with reduced ejection fraction (HFrEF) develops when cardiac output falls as a result of cardiac injury. The most well-recognized of the compensatory homeostatic responses to a fall in cardiac output are activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS). In the short term, these 'neurohormonal' systems induce a number of changes in the heart, kidneys, and vasculature that are designed to maintain cardiovascular homeostasis. However, with chronic activation, these responses result in haemodynamic stress and exert deleterious effects on the heart and the circulation. Neurohormonal activation is now known to be one of the most important mechanisms underlying the progression of heart failure, and therapeutic antagonism of neurohormonal systems has become the cornerstone of contemporary pharmacotherapy for heart failure. In this Review, we discuss the effects of neurohormonal activation in HFrEF and highlight the mechanisms by which these systems contribute to disease progression.

Citing Articles

Clinical Insights from Proteomics in Heart Failure.

Lotfinaghsh A, Imam A, Pompian A, Stitziel N, Javaheri A Curr Heart Fail Rep. 2025; 22(1):12.

PMID: 40063168 DOI: 10.1007/s11897-025-00698-w.

A Genetic Test to Identify People at High Risk of Heart Failure.

Ge X, Brittain B, Dawson L, Dwivedi G, Kaye D, Morahan G Int J Mol Sci. 2025; 26(4).

PMID: 40004245 PMC: 11855781. DOI: 10.3390/ijms26041782.

Increased risk of chronic diseases and multimorbidity in middle-aged and elderly individuals with early vision, hearing, or dual sensory impairments: insights from prospective cohort studies and Mendelian randomization analysis.

Wang Y, Cheng F, Hou N, Tan Y, Zhang S, Hou Y BMC Med. 2025; 23(1):118.

PMID: 40001102 PMC: 11863693. DOI: 10.1186/s12916-025-03857-x.

Diagnosis and Management of Hypertensive Heart Disease: Incorporating 2023 European Society of Hypertension and 2024 European Society of Cardiology Guideline Updates.

Wang B J Cardiovasc Dev Dis. 2025; 12(2).

PMID: 39997480 PMC: 11856785. DOI: 10.3390/jcdd12020046.

Upregulated LIMD1 alleviates pressure overload-induced cardiac hypertrophy via inhibits YAP1/AKT/GSK3β signaling.

Xie F, Yuan B, Zhang Y, Chen L, Zhong Y, Xu Q PLoS One. 2025; 20(2):e0316149.

PMID: 39937832 PMC: 11819601. DOI: 10.1371/journal.pone.0316149.

References

Packer M . The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992; 20(1):248-54. DOI: 10.1016/0735-1097(92)90167-l. View

Brilla C, Funck R, Rupp H . Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000; 102(12):1388-93. DOI: 10.1161/01.cir.102.12.1388. View

Izawa H, Murohara T, Nagata K, Isobe S, Asano H, Amano T . Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation. 2005; 112(19):2940-5. DOI: 10.1161/CIRCULATIONAHA.105.571653. View

Lymperopoulos A, Rengo G, Koch W . Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res. 2013; 113(6):739-53. PMC: 3843360. DOI: 10.1161/CIRCRESAHA.113.300308. View

Zannad F, Alla F, Dousset B, Perez A, Pitt B . Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000; 102(22):2700-6. DOI: 10.1161/01.cir.102.22.2700. View

Marx S, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N . PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 2000; 101(4):365-76. DOI: 10.1016/s0092-8674(00)80847-8. View

Bristow M, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R . Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986; 59(3):297-309. DOI: 10.1161/01.res.59.3.297. View

Bekheirnia M, Schrier R . Pathophysiology of water and sodium retention: edematous states with normal kidney function. Curr Opin Pharmacol. 2006; 6(2):202-7. DOI: 10.1016/j.coph.2005.09.008. View

Esteban V, Ruperez M, Sanchez-Lopez E, Rodriguez-Vita J, Lorenzo O, Demaegdt H . Angiotensin IV activates the nuclear transcription factor-kappaB and related proinflammatory genes in vascular smooth muscle cells. Circ Res. 2005; 96(9):965-73. DOI: 10.1161/01.RES.0000166326.91395.74. View

10.

Adams J, Sakata Y, Davis M, Sah V, Wang Y, Liggett S . Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci U S A. 1998; 95(17):10140-5. PMC: 21475. DOI: 10.1073/pnas.95.17.10140. View

11.

Reiken S, Wehrens X, Vest J, Barbone A, Klotz S, Mancini D . Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation. 2003; 107(19):2459-66. DOI: 10.1161/01.CIR.0000068316.53218.49. View

12.

Shah A, Mann D . In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet. 2011; 378(9792):704-12. PMC: 3486638. DOI: 10.1016/S0140-6736(11)60894-5. View

13.

Schrier R . Aldosterone 'escape' vs 'breakthrough'. Nat Rev Nephrol. 2010; 6(2):61. DOI: 10.1038/nrneph.2009.228. View

14.

Bristow M, Ginsburg R, Minobe W, Cubicciotti R, Sageman W, Lurie K . Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982; 307(4):205-11. DOI: 10.1056/NEJM198207223070401. View

15.

Iaccarino G, Tomhave E, Lefkowitz R, Koch W . Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. Circulation. 1998; 98(17):1783-9. DOI: 10.1161/01.cir.98.17.1783. View

16.

Bomback A, Klemmer P . The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007; 3(9):486-92. DOI: 10.1038/ncpneph0575. View

17.

Ma X, Liu H, Foyil S, Godar R, Weinheimer C, Hill J . Impaired autophagosome clearance contributes to cardiomyocyte death in ischemia/reperfusion injury. Circulation. 2012; 125(25):3170-81. PMC: 3397471. DOI: 10.1161/CIRCULATIONAHA.111.041814. View

18.

Hasenfuss G, Reinecke H, Studer R, Meyer M, Pieske B, Holtz J . Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium. Circ Res. 1994; 75(3):434-42. DOI: 10.1161/01.res.75.3.434. View

19.

Li Y, Feldman A, Sun Y, McTiernan C . Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation. 1998; 98(17):1728-34. DOI: 10.1161/01.cir.98.17.1728. View

20.

Creemers E, Davis J, Parkhurst A, Leenders P, Dowdy K, Hapke E . Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol. 2002; 284(1):H364-71. DOI: 10.1152/ajpheart.00511.2002. View